Vertex Pharmaceuticals Incorporated
VRTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Vertex Pharmaceuticals Incorporated (VRTX) is listed under Biotechnology. The company carries a $123.26B market cap, placing it firmly in the large-cap category. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Market Cap
$123.26B
Beta
0.29
P/E (TTM)
28.82
P/E (Fwd)
22.68
EPS (TTM)
$16.85
EPS (Fwd)
$21.41
ROE
24.2%
ROA
12.1%
Cash
$7.25B
Total Debt
$1.99B
Free CF
$2.78B
52W Change
5.6%
Annual Financials
Cash vs Debt
With $7.25B in cash and $1.99B in debt, VRTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $2.78B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 24.2%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 12.1% further supports the picture of efficient asset utilization. Revenue has grown from $8.93B (2022) to $12.00B (2025), reflecting a 34% increase over the period.
VRTX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vertex Pharmaceuticals Incorporated and its sector.